SCHEMBL20127342

SCHEMBL20127342

c1ccc(-c2c3ccccc3c(-c3ccc4c(ccc5oc6ccccc6c54)c3)c3ccccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ABCG2 Q9UNQ0 5/20 0.42
CYP1A2 P05177 2/20 0.42
AHR P35869 2/20 0.42
PAX8 Q06710 2/20 0.42
CYP1A1 P04798 1/20 0.42
FYN P06241 1/20 0.42
MAPK3 P27361 1/20 0.42
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
PGR P06401 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HSD17B1 P14061 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B2 P37059 1/20 0.39
CA1 P00915 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20412618 0.98 ESR1 (0.42) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL22062653 0.96 PLA2G2A (0.43) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL22062818 0.95 ESR1 (0.46) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL20127505 0.94 PGR (0.44) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL20127343 0.93 PGR (0.43) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL20127474 0.91 TDP1 (0.50) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL20127488 0.91 MAPT (0.44) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL20127484 0.91 AHR (0.44) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL20127334 0.91 TDP1 (0.46) TDP1L3MBTL1ABCG2CYP1A2AHR
SCHEMBL20127476 0.91 TDP1 (0.43) TDP1L3MBTL1ABCG2CYP1A2AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210320251-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPLIANCE IDEMITSU KOSAN CO.,LTD. (JP) 2021-10-14 US disclosed
US-20200212315-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE, AND COMPOUND IDEMITSU KOSAN CO.,LTD. (JP) 2020-07-02 US disclosed
US-20200185620-A1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2020-06-11 US disclosed
US-20180208836-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-07-26 US disclosed
US-20180208836-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-07-26 US disclosed
US-20180130968-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-05-10 US disclosed
US-20180130968-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180130968-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE RER1, NR0B1, NR2E1 TDP1 3427/4885L3MBTL1 1670/4885ABCG2 3284/4885
US-20210320251-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPLIANCE OLA1, TAS2R19, TMEM109 TDP1 2737/4885L3MBTL1 2341/4885ABCG2 4638/4885
US-20200212315-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE, AND COMPOUND OR10J3, ESR1, NFE2L2 TDP1 4110/4885L3MBTL1 713/4885ABCG2 4215/4885
US-20200185620-A1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE EMC2, NFE2L2, AOC2 TDP1 4482/4885L3MBTL1 3064/4885ABCG2 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.